Skip to main content

Medtronic buys sinus-implant company for over $1 billion

Intersect ENT (NASDAQ: XENT) makes implants that open sinus passageways and deliver an anti-inflammatory steroid to help patients who suffer from chronic rhinosinusitits (CRS).
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.